• Press Release

Paul Kenny, PhD, Recognized for Outstanding Basic Research Contributions to Neuropsychopharmacology

  • New York, NY
  • (December 13, 2018)

Paul Kenny, PhD, the Ward-Coleman Professor and Chair of the Department of Neuroscience at the Icahn School of Medicine at Mount Sinai, has been awarded the 2018 Daniel H. Efron Research Award from the American College of Neuropsychopharmacology (ACNP).  The award is given in recognition of outstanding basic research contributions to neuropsychopharmacology. Dr. Kenny was presented the award at the 57th Annual Meeting of the ACNP in Hollywood, Florida, on Monday, December 10.

In addition to his role as Chair of Neuroscience, Dr. Kenny serves as Director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai.  His lab is focused on understanding the neurobiological mechanisms of drug addiction, obesity, and schizophrenia, with an emphasis on the role of nicotinic acetylcholine receptors in these processes. Dr. Kenny is also involved in efforts to develop novel small-molecule therapeutic agents for the treatment of drug addiction and other psychiatric indications, and is co-founder of Eolas Therapeutics, Inc., a company committed to treating the disease of addiction.

Over the past decade, Dr. Kenny has made outstanding contributions to neuropharmacology and the molecular study of addiction. He has won numerous awards, which include Young and Distinguished Investigator Awards from the National Alliance for Research on Schizophrenia and Depression, the Jarvik-Russell Award from the Society for Research on Nicotine and Tobacco, and the Jacob P. Waletzky Memorial Award from the Society for Neuroscience. He has also received the Tom Connor Distinguished Investigator Award from Neuroscience Ireland.

“Dr. Kenny is absolutely spectacular. He has the highest of ethical standards and he has earned the respect of his colleagues and peers,” said Eric J. Nestler, MD, PhD, Dean for Academic and Scientific Affairs at the Icahn School of Medicine at Mount Sinai and Director of The Friedman Brain Institute at Mount Sinai. “I am confident that his world-class research program will continue to make ground-breaking contributions to our understanding of drug addiction, discoveries that could rapidly set the stage for the development of novel therapeutic interventions.”

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.